

Robert Alexander Ingram: Executive Profile & Biography - Bloomberg









































  





















































































July 22, 2017 8:30 AM ET
Capital Markets

Company Overview of Hatteras Venture Partners



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Robert Alexander Ingram  General Partner and Partner, Hatteras Venture PartnersAgeTotal Calculated CompensationThis person is connected to 16 Board Members in 16 different organizations across 26 different industries.See Board Relationships74--
Background

		Mr. Robert Alexander Ingram, also known as Bob, has been a General Partner of Hatteras Venture Partners since January 24, 2007 and serves as its Partner. Mr. Ingram served as a Special Advisor to Chairman, Chief Executive Officer and President of SillaJen Biotherapeutics, Inc. He is a Senior Advisor of GHO Capital Partners LLP. He served at GlaxoSmithKline plc from 1990 to 2010 and served as Advisor to the Chief Executive Officer since January 2010, Special Consultant ... at GlaxoSmithKline plc and Strategic Advisor to the Chief Executive Officer. He served as the Chief Operating Officer and President of Pharmaceutical Operations at GlaxoSmithKline PLC (GSK) from January 2001 to January 2003 and acting as a special advisor to the Corporate Executive Team and attending its meetings from January 2003 to December 2009. He served as a Vice Chairman of Pharmaceuticals from 2003 to 2009 and President and Chief Operating Officer of pharmaceutical operations from 2001 to 2003. He served as the President and Chief Executive Officer of Glaxo Wellcome Plc from October 1997 to January 1999 and as Chief Executive Officer of Glaxo Wellcome Inc. from 1994 to January 2000. He served as the Chairman of Glaxo Wellcome Inc from January 1999 to December 2000. He served as the Chairman of Glaxo Wellcome PLC from January 1999 to December 2000. He held several executive positions at Glaxo Wellcome plc from 1990 and 1999. Mr. Ingram served as an Executive Director of Glaxo Wellcome PLC from September 1996 to October 1997. He served as an Executive Vice President of Glaxo Inc. since January 1993, its Chief Operating Officer and President since June 1993, Chief Executive Officer since March 1994. Since 1988, he served as the President of Merck Frosst Canada Inc. Since 1990, he joined Glaxo Inc., as Executive Vice President of Administrative & Regulatory Affairs and assumed a series of increasingly responsible positions, including Group Vice President. Mr. Ingram served as Chairman of Glaxo Inc since January 1999. He co-led the merger and integration that formed GlaxoSmithKline and served as the Vice Chairman of Pharmaceuticals at GSK from January 2003 to January 1, 2010. He began his career in the pharmaceutical industry as a sales representative at OSI Pharmaceuticals Inc., which became Merrell Dow Pharmaceuticals. He advanced rapidly through sales management at Merrell Dow and into government and public affairs. He left Merrell Dow since 1985 as Vice President of Public Affairs. He served as the Vice President of Government Affairs at Merck & Co. Inc since 1985. He has been the Chairman at Viamet Pharmaceuticals Holdings, LLC since October 21, 2014. Mr. Ingram served as the Non-Executive Chairman of Elan Corporation, plc since January 26, 2011 and served as Non-Executive Director since December 3, 2010. He served as Chairman of Valeant Pharmaceuticals International, Inc from December 2010 to March 2011. He served as Non Executive Chairman of OSI Pharmaceuticals Inc since January 1, 2003. He serves as a Member of Strategic Advisory Board of Audax Health Solutions, Inc and Decision Sciences Medical Corporation. He serves as a Director of HBM Partners Ltd. He has been Lead Independent Director at Cree, Inc. since October 2011 and also its Independent Director since December 29, 2008. He is the Chairman at Novan Inc. since 2011. He has been Interim Chairman of Valeant Pharmaceuticals International, Inc since January 6, 2016. He has been a Member of the Board of Directors of Quintiles Transnational Corp. since March 1, 2004. He serves as a Director of Jim “Catfish” Hunter Chapter of ALS Association. He serves as a Director of PhaseBio Pharmaceuticals, Inc. Mr. Ingram serves as a Director of TheraCom, Inc and Project Hope. He is a Member of the Boards for GlaxoSmithKline Foundation. He serves as a Member of the International Advisory Council at Chugai Pharmaceutical Co. Ltd. He is a Member of the Board of Advisors for the H. Lee Moffitt Cancer Center and Research Institute. He has been Director of BioCryst Pharmaceuticals, Inc since August 2015 and has been its Chairman since May 24, 2017. He has been a Director of Wells Fargo Corporation since 1997. He has been Member of Board of Governors of Research Triangle Institute since December 2010. He serves as a Director of Partnership for Public Service. He serves as the Lead Independent Director of Valeant Pharmaceuticals. He served as an Independent Director of Valeant Pharmaceuticals International, Inc. from September 28, 2010 until May 2, 2017. He served as a Lead Director of Valeant Pharmaceuticals International, Inc. from March 2011 to June 15, 2016 and previously served as its Lead Director from September 2010 to December 2010. He served as Director of Pharmaceutical Product Development, LLC since May 18, 2011. Mr. Ingram is a member of the boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center and Chief Executive Officer Roundtable on Cancer. He serves as the Chairman of the Board of Glaxo North Carolina Foundation. He serves as Chairman of Research Triangle Foundation of North Carolina and is on the Advisory Board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California. He has been Independent Non-Executive Director at Malin Corporation plc since February 12, 2015. He served as an Independent Director of Edwards Lifesciences Corp. from February 20, 2003 to July 30, 2015. He served as a Director of Wachovia Corporation since 1997; Allergan Inc. from January 25, 2005 to December 10, 2012; Lowe's Companies Inc. from 2001 to May 27, 2011 and Molson Inc. from June 19, 2002 to July 28, 2004. He served as an Independent Director of Nortel Networks Corporation from March 7, 2000 to June 29, 2006 and Nortel Networks Ltd. from April 29, 1999 to June 29, 2006. He served as a Director of Wachovia Securities, Inc. since 1997 and Nortel Networks Netas Telekomunikasyon AS. Mr. Ingram served as a Director of Wells Fargo Bank, N.A., Charlotte (Wachovia Bank, National Association (Charlotte, NC)). He served as Non-Executive Director of Misys Limited from January 2002 to September 13, 2005. He served as Director of Regeneron Pharmaceuticals, Inc. from April, 2014 to November 10, 2015. He served as the Chairman of the Board of Trustees of the American Cancer Society Foundation and American Cancer Society, Inc. He is frequent speaker at industry, pharmacy and government seminars. In January 2004, he was awarded the Martin Luther King, Jr. Legacy Award for International Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. Mr. Ingram graduated from Eastern Illinois University, Lumpkin College of Business, Charleston, Illinois in 1965 with B.Sc. degree in Business Administration.Read Full Background




Corporate Headquarters
280 South Mangum StreetDurham, North Carolina 27701United StatesPhone: 919-484-0730Fax: 919-484-0364
Board Members Memberships
DirectorPhaseBio Pharmaceuticals, Inc.DirectorHBM Partners Ltd.DirectorPartnership for Public ServiceChairmanViamet Pharmaceuticals, Inc.1997-PresentIndependent DirectorWells Fargo Corporation2004-PresentDirectorQuintiles Transnational Corp.2006-PresentMember of Board of DirectorsHBM Healthcare Investments AG2008-PresentLead Independent DirectorCree, Inc.2014-PresentChairmanViamet Pharmaceuticals Holdings, LLC2015-PresentChairmanBioCryst Pharmaceuticals, Inc.2015-PresentIndependent Non-Executive DirectorMalin Corporation plc
Education
BSBA 1965Eastern Illinois University
Other Affiliations
BioCryst Pharmaceuticals, Inc.Quintiles Transnational Corp.Regeneron Pharmaceuticals, Inc.Pharmaceutical Product Development, LLCValeant Pharmaceuticals InternationalNortel Networks CorporationAmerican Cancer Society, Inc.Wells Fargo CorporationLowe's Companies, Inc.Wachovia Corp., Prior to the acquisition by First Union CorporationCree, Inc.Allergan, Inc.Elan Corporation LimitedGlaxoSmithKline plcOSI Pharmaceuticals Inc.Valeant Pharmaceuticals International, Inc.Edwards Lifesciences CorporationChugai Pharmaceutical Co., Ltd.Molson Inc.Finastra Group Holdings LimitedHBM Healthcare Investments AGResearch Triangle InstituteWells Fargo Bank, N.A., CharlotteNortel Networks Ltd.PhaseBio Pharmaceuticals, Inc.Eastern Illinois UniversityWachovia Securities, Inc, prior to being acq. by First UnionHBM Partners Ltd.Partnership for Public ServiceProsidion LimitedALS AssociationViamet Pharmaceuticals, Inc.SillaJen Biotherapeutics, Inc.Hatteras Venture Partners III, L.P.Rally Health, Inc.Viamet Pharmaceuticals Holdings, LLCDecision Sciences Medical CorporationGHO Capital Partners LLPMalin Corporation plc


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Hatteras Venture Partners, please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























VRX Robert Alexander Ingram Insider Trades for Valeant Pharmaceuticals International Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Valeant Pharmaceuticals International Inc.

                  NYSE: VRX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Valeant Pharmaceuticals International Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 7:59 p.m.


VRX

/quotes/zigman/122461/composite


$
17.57




Change

+0.07
+0.40%

Volume
Volume 210,098
Quotes are delayed by 20 min








/quotes/zigman/122461/composite
Previous close

$
			17.60
		


$
				17.50
			
Change

-0.10
-0.57%





Day low
Day high
$17.31
$17.71










52 week low
52 week high

            $8.31
        

            $32.75
        


















Insider Activity


Individual




Robert Alexander Ingram



Mr. Robert Alexander Ingram is Chairman at Viamet Pharmaceuticals Holdings LLC, Lead Independent Director at Cree, Inc., Lead Independent Director at Valeant Pharmaceuticals International, Inc., General Partner at Hatteras Venture Partners, Chairman at American Foundation for Pharmaceutical Education, a Member at Business-Higher Education Forum, Chairman at Elan Pharmaceuticals, Inc., Chairman at Research Triangle Foundation, Chairman at North Carolina Glaxosmithkline Foundation, Chairman at Viamet Pharmaceuticals, Inc., and Chairman at GlaxoSmithKline Foundation. He is on the Board of Directors at BioCryst Pharmaceuticals, Inc., Cree, Inc., HBM Healthcare Investments AG, Valeant Pharmaceuticals International, Inc., American Cancer Society Foundation, CEO Roundtable on Cancer, Inc., Project HOPE-The-People-To-People HealthFoundation, Inc., Research Triangle Institute, PhaseBio Pharmaceuticals, Inc., Malin Corp. Plc, James B. Hunt Jr. Institute for Educational Leadership & Poli, and H. Lee Moffitt Cancer Center & Research Institute, Inc.
Mr. Ingram was previously employed as Independent Director by Regeneron Pharmaceuticals, Inc., Non-Executive Chairman by Elan Corp. Plc, Independent Director by Allergan, Inc., Independent Director by Edwards Lifesciences Corp., Chairman by OSI Pharmaceuticals, Inc., Non-Executive Director by Misys Plc, Vice Chairman-Pharmaceuticals by Smithkline Beecham Corp., Chief Executive Officer by Glaxo Wellcome Plc, Chairman by Glaxo, Inc., President by Merck Frosst Canada Ltd., Chairman, President & Chief Executive Officer by Glaxo Wellcome, Inc., a Principal by National Institutes of Health, and Vice President-Public Affairs by Merrell Dow Pharmaceuticals, Inc. He also served on the board at Lowe's Cos., Inc., Wachovia Corp., ICN Pharmaceuticals, Inc., Nortel Networks Corp., Pharmaceutical Product Development LLC, and Quintiles Transnational Corp.
He received his undergraduate degree from Eastern Illinois University.



Transactions


Date
Shares
Transaction
Value





03/31/2017
2,120


 
Award at $11.03 per share.


23,383


12/30/2016
1,463


 
Award at $14.52 per share.


21,242


09/30/2016
865


 
Award at $24.55 per share.


21,235


06/30/2016
1,080


 
Award at $20.14 per share.


21,751


06/17/2016
16,726


 
Award at $0 per share.


0


05/02/2016
926


 
Award at $0 per share.


0


12/31/2015
239


 
Award at $0 per share.


0


09/30/2015
136


 
Award at $0 per share.


0


06/30/2015
109


 
Award at $0 per share.


0


05/22/2015
1,607


 
Award at $0 per share.


0


03/31/2015
122


 
Award at $0 per share.


0


05/23/2014
2,866


 
Award at $0 per share.


0


06/04/2013
1,279


 
Derivative/Non-derivative trans. at $88.21 per share.


112,821


05/30/2013
127,128


 



11,544,494


05/24/2013
5,022


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Joseph C. Papa 
Chairman & Chief Executive Officer




Mr. Paul S. Herendeen 
Chief Financial Officer & Executive VP-Finance




Dr. Tage  Ramakrishna 
Chief Medical Officer, President-R&D




Mr. William D. Humphries 
Executive Vice President-Dermatology




Dr. Louis W. Yu 
Chief Quality Officer




Mr. Fernando  Zarate 
General Manager-Valeant Mexico




Mr. John Alfred Paulson 
Director




Mr. William Albert Ackman 
Director




Mr. Robert Alexander Ingram 
Director




Ms. Stacey  Williams 
Vice President-Marketing




Mr. Michael  McMyne 
Vice President-Sales




Mr. Eric  Abramson 
VP-Marketing Dermatology & Immunology




Mr. Sam  Eldessouky 
Chief Accounting Officer, Senior VP & Controller




Mr. Arthur J. Shannon 
SVP, Head-Investor Relations & Communications




Ms. Lainie  Keller 
Vice President-Corporate Communications




Ms. Elif  McDonald 
Director-Investor Relations




Mr. Scott A. Hirsch 
Senior VP-Business Strategy & Communications




Mr. Kelly  Webber 
Senior Vice President-Human Resources




Ms. Christina M. Ackermann 
Executive Vice President & General Counsel




Mr. Richard U. de Schutter 
Independent Director




Ms. Sarah B. Kavanagh 
Independent Director




Mr. David Robert Hale 
Independent Director




Dr. Amy B. Wechsler 
Independent Director




Mr. Russel C. Robertson 
Independent Director




Dr. Argeris N. Karabelas 
Independent Director




Mr. Thomas W. Ross 
Lead Independent Director




Mr. Stephen  Fraidin 
Independent Director




Dr. Fredric N. Eshelman 
Independent Director




Mr. Robert N. Power 
Independent Director




Ms. Katharine Berghuis Stevenson 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




8:31 AM EDT
July 22, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
8:26aEuro rally has room to run if this pattern continues to hold true
8:25aWeekend roundup: Companies that may cut dividends | FAANG stocks and market bubbles | Enjoy London on the cheap
8:25aAttention, shoppers: ‘Amazon effect’ is creating bargain stocks
8:25aWhy you might want to avoid these 30 dividend stocks
8:21aStocks brace for volatility in earnings deluge; Fed meeting looms 
8:15a9 charts that capture how the rest of the world feels about Donald Trump
6:00a4 questions you should never answer at work
6:00aThe shocking amount guests now have to spend to attend a wedding
8:34pCharges dropped after ‘London Whale’ accused Jamie Dimon of making him a fall guy
7:41pGoodbye, Sean Spicer: Memorable Moments From the Podium  
7:18pHow to Fix Wall Street, and Bankers' Pay
6:59pAmazon, Whole Foods look to head off lengthy deal review
6:45pHawaii adopts emergency plan for North Korea missile attack
6:24p California Wildfire Destroys Homes Near Yosemite
6:20pSpicer Quits as Scaramucci Accepts White House Job
6:20pWhy you shouldn’t order ice on a flight, and other ‘dirty little secrets’ 
6:09pIf you’re reading this, you have a 19.3% chance of being rich
6:07p5 unfortunate reasons why millennials can’t have nice things (or save any money)
6:06pThis is the deadliest time of your life to put on weight
6:06pIf, like Sean Spicer, you suddenly walk out — what should you do next?
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































BCRX Robert Alexander Ingram Insider Trades for BioCryst Pharmaceuticals Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































BioCryst Pharmaceuticals Inc.

                  NASDAQ: BCRX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

BioCryst Pharmaceuticals Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 4:33 p.m.


BCRX

/quotes/zigman/54089/composite


$
5.41




Change

-0.0011
-0.02%

Volume
Volume 9,340
Quotes are delayed by 20 min








/quotes/zigman/54089/composite
Previous close

$
			5.57
		


$
				5.41
			
Change

-0.16
-2.87%





Day low
Day high
$5.38
$5.67










52 week low
52 week high

            $2.95
        

            $9.25
        


















Insider Activity


Individual




Robert Alexander Ingram



Mr. Robert A. Ingram is Chairman at Viamet Pharmaceuticals Corp., Chairman at Novan, Inc., Chairman at Elan Pharmaceuticals, Inc., Chairman at GlaxoSmithKline Foundation, Chairman at North Carolina Glaxosmithkline Foundation, Chairman at Research Triangle Foundation, Chairman at Viamet Pharmaceuticals, Inc., General Partner at Hatteras Venture Partners and a Member at Business-Higher Education Forum. He is on the Board of Directors at BioCryst Pharmaceuticals, Inc., Malin Corp. Plc, Cree, Inc., HBM Healthcare Investments AG, Valeant Pharmaceuticals International, Inc., James B. Hunt Jr. Institute for Educational Leadership & Poli, PhaseBio Pharmaceuticals, Inc., Project HOPE-The-People-To-People HealthFoundation, Inc., Research Triangle Institute, American Cancer Society Foundation and CEO Roundtable on Cancer, Inc. 
Mr. Ingram was previously employed as an Independent Director by Regeneron Pharmaceuticals, Inc., Non-Executive Chairman by Elan Corp. Plc, an Independent Director by Allergan, Inc., an Independent Director by Edwards Lifesciences Corp., Chairman by OSI Pharmaceuticals, Inc., Non-Executive Director by Misys Plc, Vice Chairman-Pharmaceuticals by Smithkline Beecham Corp., Chief Executive Officer by Glaxo Wellcome Plc, Chairman by Glaxo, Inc., President by Merck Frosst Canada Ltd., Chairman by American Foundation for Pharmaceutical Education, Chairman, President & Chief Executive Officer by Glaxo Wellcome, Inc., Vice President-Public Affairs by Merrell Dow Pharmaceuticals, Inc., a Principal by National Institutes of Health, and Chairman by Novan, Inc. He also served on the board at Lowe's Cos., Inc., Wachovia Corp., H. Lee Moffitt Cancer Center & Research Institute, Inc., ICN Pharmaceuticals, Inc. /Old/, Nortel Networks Corp., Pharmaceutical Product Development LLC and Quintiles Transnational Corp. 
Mr. Ingram received his BS degree in Business Administration from Eastern Illinois University.



Transactions


Date
Shares
Transaction
Value





06/01/2017
1,941


 
Award at $5.15 per share.


9,996


03/02/2017
1,602


 
Award at $6.24 per share.


9,996


12/01/2016
1,788


 
Award at $5.59 per share.


9,994


09/01/2016
2,433


 
Award at $4.11 per share.


9,999





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Robert Alexander Ingram 
Chairman




Mr. Jon P. Stonehouse 
President, Chief Executive Officer & Director




Mr. Robert  Bennett 
Vice President-Investor Relations & Operations




Mr. Thomas R. Staab 
CFO, Treasurer, Principal Accounting Officer & SVP




Dr. William P. Sheridan 
Chief Medical Officer & Senior Vice President




Ms. Lynne M. Powell 
Chief Commercial Officer & Senior Vice President




Dr. Yarlagadda S. Babu 
Senior Vice President-Drug Discovery




Mr. Robert C. Stoner 
Vice President-Human Resources




Ms. Alane P. Barnes 
Secretary, Vice President & General Counsel




Dr. Elliott T. Berger 
Senior Vice President-Regulatory Affairs




Mr. George B. Abercrombie 
Director




Mr. Sanj K.  Patel 
Independent Director




Dr. Fred E. Cohen 
Independent Director




Dr. Nancy J. Hutson 
Independent Director




Mr. Kenneth B. Lee 
Independent Director




Mr. Stanley C. Erck 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




8:31 AM EDT
July 22, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
8:26aEuro rally has room to run if this pattern continues to hold true
8:25aWeekend roundup: Companies that may cut dividends | FAANG stocks and market bubbles | Enjoy London on the cheap
8:25aAttention, shoppers: ‘Amazon effect’ is creating bargain stocks
8:25aWhy you might want to avoid these 30 dividend stocks
8:21aStocks brace for volatility in earnings deluge; Fed meeting looms 
8:15a9 charts that capture how the rest of the world feels about Donald Trump
6:00a4 questions you should never answer at work
6:00aThe shocking amount guests now have to spend to attend a wedding
8:34pCharges dropped after ‘London Whale’ accused Jamie Dimon of making him a fall guy
7:41pGoodbye, Sean Spicer: Memorable Moments From the Podium  
7:18pHow to Fix Wall Street, and Bankers' Pay
6:59pAmazon, Whole Foods look to head off lengthy deal review
6:45pHawaii adopts emergency plan for North Korea missile attack
6:24p California Wildfire Destroys Homes Near Yosemite
6:20pSpicer Quits as Scaramucci Accepts White House Job
6:20pWhy you shouldn’t order ice on a flight, and other ‘dirty little secrets’ 
6:09pIf you’re reading this, you have a 19.3% chance of being rich
6:07p5 unfortunate reasons why millennials can’t have nice things (or save any money)
6:06pThis is the deadliest time of your life to put on weight
6:06pIf, like Sean Spicer, you suddenly walk out — what should you do next?
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Insider Trading - Ingram Robert Alexander - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Ingram Robert Alexander





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-06-07Purchase
2016-06-074:38 pm
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
107,142
$7
$749,994
1,783,020(Indirect)
View


2016-06-07Sale
2016-06-074:38 pm
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
69
$7
$483
1,783,020(Indirect)
View


2016-06-07Purchase
2016-06-074:35 pm
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
414,286
$7
$2,900,002
2,090,170(Indirect)
View


2016-06-07Sale
2016-06-074:35 pm
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
69
$7
$483
2,090,170(Indirect)
View


2015-12-01Sale
2015-12-034:09 pm
Cree Inc
CREE
Ingram Robert AlexanderDirector
3,750
$27.67
$103,755
52,596(Direct)
View


2015-05-22Sale
2015-05-274:02 pm
Regeneron Pharmaceuticals Inc
REGN
Ingram Robert AlexanderDirector
1,379
$513.4
$707,965
13,333(Direct)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-12-30Option Award
2017-01-047:45 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
1,463
$14.52
89,926(Direct)
View


2016-12-01Option Award
2016-12-022:09 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Ingram Robert AlexanderDirector
1,788
$5.59
4,221(Direct)
View


2016-10-19Option Award
2016-10-204:33 pm
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
1,115
$22.41
59,817(Direct)
View


2016-09-30Option Award
2016-10-054:07 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
865
$24.55
88,463(Direct)
View


2016-09-26Conversion
2016-09-286:32 pm
N/AN/A
Novan Inc.
NOVN
Ingram Robert AlexanderDirector
27,777
$0
57,777(Direct)
View


2016-09-26Conversion
2016-09-286:32 pm
N/AN/A
Novan Inc.
NOVN
Ingram Robert AlexanderDirector
27,777
$0
57,777(Direct)
View


2016-09-20Option Award
2016-09-224:44 pm
N/A2026-09-19
Novan Inc.
NOVN
Ingram Robert AlexanderDirector
14,484
$11
14,484(Direct)
View


2016-09-01Option Award
2016-09-065:11 pm
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
6,429
$0
58,702(Direct)
View


2016-09-01Option Award
2016-09-063:27 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Ingram Robert AlexanderDirector
2,433
$4.11
2,433(Direct)
View


2016-08-17Option Award
2016-08-184:43 pm
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
1,229
$23.38
52,273(Direct)
View


2016-06-30Option Award
2016-07-116:38 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
1,080
$20.14
87,598(Direct)
View


2016-06-17Option Award
2016-06-218:15 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
16,726
$0
86,518(Direct)
View


2016-06-07Conversion
2016-06-074:38 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
1,598,219
$0
1,783,020(Indirect)
View


2016-06-07Exercise
2016-06-074:38 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
21,705
$0.022
1,783,020(Indirect)
View


2016-06-07Conversion
2016-06-074:38 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
2,035,907
$0
1,783,020(Indirect)
View


2016-06-07Conversion
2016-06-074:38 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
689,388
$0
1,783,020(Indirect)
View


2016-06-07Conversion
2016-06-074:38 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
432,940
$0
1,783,020(Indirect)
View


2016-06-07Conversion
2016-06-074:38 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
337,898
$0
1,783,020(Indirect)
View


2016-06-07Exercise
2016-06-074:38 pm
2014-04-28N/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
19,900
$0.022
1,783,020(Indirect)
View


2016-06-07Exercise
2016-06-074:38 pm
2014-04-28N/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors III LLCHatteras Ventures Partners III LpHatteras Venture Affiliates III LpCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp Clay10% Owner
1,805
$0.022
1,783,020(Indirect)
View


2016-06-07Conversion
2016-06-074:35 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
1,598,223
$0
2,090,170(Indirect)
View


2016-06-07Exercise
2016-06-074:35 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
21,705
$0.022
2,090,170(Indirect)
View


2016-06-07Conversion
2016-06-074:35 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
2,035,908
$0
2,090,170(Indirect)
View


2016-06-07Conversion
2016-06-074:35 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
689,388
$0
2,090,170(Indirect)
View


2016-06-07Conversion
2016-06-074:35 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
432,941
$0
2,090,170(Indirect)
View


2016-06-07Conversion
2016-06-074:35 pm
N/AN/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
337,897
$0
2,090,170(Indirect)
View


2016-06-07Exercise
2016-06-074:35 pm
2014-04-28N/A
Clearside Biomedical Inc.
CLSD
Hatteras Venture Advisors Iv Sbic LLCCrumpler JohnReed Douglas MdLee Kenneth B JrIngram Robert AlexanderThorp ClayHatteras Venture Partners Iv Sbic Lp10% Owner
21,705
$0.022
2,090,170(Indirect)
View


2016-05-23Option Award
2016-05-253:15 pm
2016-06-232026-05-23
Biocryst Pharmaceuticals Inc
BCRX
Ingram Robert AlexanderDirector
30,000
$3.22
30,000(Direct)
View


2016-05-02Option Award
2016-05-045:09 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
926
$0
69,792(Direct)
View


2016-04-27Option Award
2016-04-295:22 pm
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
1,105
$26
51,044(Direct)
View


2016-01-20Option Award
2016-01-2210:23 am
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
1,093
$26.3
49,939(Direct)
View


2015-12-31Option Award
2016-01-045:49 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
239
$0
68,866(Direct)
View


2015-12-01Exercise
2015-12-034:09 pm
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
3,750
$14.71
52,596(Direct)
View


2015-12-01Exercise
2015-12-034:09 pm
2009-09-302015-12-29
Cree Inc
CREE
Ingram Robert AlexanderDirector
3,750
$14.71
52,596(Direct)
View


2015-10-21Option Award
2015-10-232:42 pm
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
1,199
$23.96
48,846(Direct)
View


2015-09-30Option Award
2015-10-024:06 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
136
$0
68,627(Direct)
View


2015-09-01Option Award
2015-09-035:37 pm
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
6,674
$0
47,647(Direct)
View


2015-08-12Option Award
2015-08-1411:16 am
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
1,112
$26.58
40,973(Direct)
View


2015-08-05Option Award
2015-08-075:13 pm
2015-09-052025-08-05
Biocryst Pharmaceuticals Inc
BCRX
Ingram Robert AlexanderDirector
18,750
$14.88
18,750(Direct)
View


2015-06-30Option Award
2015-07-027:11 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
109
$0
68,491(Direct)
View


2015-05-22Exercise
2015-05-274:02 pm
N/AN/A
Regeneron Pharmaceuticals Inc
REGN
Ingram Robert AlexanderDirector
6,667
$293.5
13,333(Direct)
View


2015-05-22Tax Withholding
2015-05-274:02 pm
N/AN/A
Regeneron Pharmaceuticals Inc
REGN
Ingram Robert AlexanderDirector
3,788
$516.5
13,333(Direct)
View


2015-05-22Exercise
2015-05-274:02 pm
N/A2024-04-04
Regeneron Pharmaceuticals Inc
REGN
Ingram Robert AlexanderDirector
6,667
$293.5
13,333(Direct)
View


2015-05-22Option Award
2015-05-273:57 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
1,607
$0
68,382(Direct)
View


2015-05-15Option Award
2015-05-194:32 pm
N/AN/A
Edwards Lifesciences Corp
EW
Ingram Robert AlexanderDirector
1,521
$0
32,367(Direct)
View


2015-05-15Option Award
2015-05-194:32 pm
N/AN/A
Edwards Lifesciences Corp
EW
Ingram Robert AlexanderDirector
305
$0
32,367(Direct)
View


2015-04-22Option Award
2015-04-2411:27 am
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
811
$32.36
39,861(Direct)
View


2015-03-31Option Award
2015-04-023:24 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Ingram Robert AlexanderDirector
122
$0
66,775(Direct)
View


2015-01-21Option Award
2015-01-234:00 pm
N/AN/A
Cree Inc
CREE
Ingram Robert AlexanderDirector
775
$33.87
39,050(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Sat, 22 Jul 2017 07:31:02 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  










ROBERT ALEXANDER  INGRAM - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











ROBERT ALEXANDER  INGRAM
Check out list of companies and businesses related to ROBERT ALEXANDER  INGRAM. Find out ROBERT ALEXANDER  INGRAM address and contact details. View other people related to ROBERT ALEXANDER  INGRAM - coworkers, colleagues, companions, etc.
Address:   

929 NORTH FRONT STREET  WILMINGTON 28401 NC




Companies related to ROBERT ALEXANDER  INGRAM
CIKCompany NamePositionCompany Address0001003124PHARMACEUTICAL PRODUCT DEVELOPMENT INCDirector 929 NORTH FRONT STREET  WILMINGTON 28401




ROBERT ALEXANDER  INGRAM on the Web
Persons related to ROBERT ALEXANDER  INGRAM - PHARMACEUTICAL PRODUCT DEVELOPMENT INCNamePositionCityLee  BabissExec. VP--Global Lab Services WILMINGTONLINDA  BADDOURChief Financial Officer WILMINGTONLINDA  BADDOURChief Financial Officer WILMINGTONLINDA  BADDOURFormer Chief Financial Officer WILMINGTONSTUART  BONDURANTDirector CHAPEL HILLVAUGHN D  BRYSONDirector WILMINGTONFrancis J  CasieriSr. VP, Global Business Dev. WILMINGTONPAUL  COLVINEVP--Clinical Development WILMINGTONPAUL S  COVINGTONExecutive Vice President WILMINGTONDaniel G  DarazsdiChief Financial Officer WILMINGTONDaniel G  DarazsdiWILMINGTONFRED B  DAVENPORT JRPresident WILMINGTONChristine A  DingivanEVP/Chief Medical Officer WILMINGTONChristine A  DingivanWILMINGTONFREDRIC N  ESHELMANCEO WILMINGTONFREDRIC N  ESHELMANExecutive Chairman WILMINGTONMARYE ANNE  FOXDirector RALEIGHMARYE ANNE  FOXDirector LA JOLLAFRED  FRANKDirector NEW YORKDAVID L  GRANGEDirector WHEATONDAVID L  GRANGEChief Executive Officer WILMINGTONJUDD  HARTMANGeneral Counsel WILMINGTONJUDD  HARTMANGeneral Counsel WILMINGTONRaymond H  HillChief Executive Officer WILMINGTONRaymond H  HillChief Executive Officer WILMINGTONROBERT ALEXANDER  INGRAMDirector WILMINGTONCATHY  KLEMADirector NEW YORKCATHY  KLEMADirector NEW YORKTERRY  MAGNUSONDirector CHAPEL HILLERNEST  MARIODirector PALO ALTOERNEST  MARIODirector PRINCETONJOHN A  MCNEILL JRDirector WHITEVILLEWilliam W  RichardsonSr. VP Global Bus. Development RALEIGHWilliam W  RichardsonSr. VP Global Bus. Development WILMINGTONCOLIN  SHANNONNEW MARKETCOLIN  SHANNONEVP, Global Clinical Ops. NEW MARKET UKCOLIN  SHANNONEVP, Global Clinical Ops WILMINGTONWilliam J  SharbaughChief Operating Officer WILMINGTONWilliam J  SharbaughWILMINGTONRALPH  SNYDERMANDirector WILMINGTONW RICHARD  STAUBSr. Vice President RALEIGHMichael O.  WilkinsonWILMINGTONMichael O.  WilkinsonChief Information Officer WILMINGTONPeter J  WilkinsonVP of Fin./Chief Acctg. Off. WILMINGTONPeter J  WilkinsonVP of Fin./Chief Acctg. Off. WILMINGTON
Potentially same personNameCityCountryAlexander  RobertSeattleWAAlexander  RobertSan FranciscoCAAlexander  RobertSan FranciscoCAAlexander  RobertAikenSCAlexander  RobertBostonMAAlexander  RobertSan MateoCAAlexander  RobertFort WorthTXAlexander  RobertGreenwood VillageCOAlexander  RobertLas VegasNVAlexander  RobertSan DiegoCAAlexander  RobertCoppellTXALEXANDER  ROBERTCOLORADO SPRINGSCOAlexander  RobertGreenwood VillageCO












 








Robert Alexander Ingram - Biography

















































































Log in






E-mail



Password







Remember




Forgot password ?









Become a member for free
Sign up





Sign up




New memberSign up for FREE


New customerDiscover our portfolios












 United States
 United Kingdom
 France
 Deutschland
 Schweiz (DE)
 Suisse (FR)










Settings

            Dynamic quotes 


OFFON

















Markets
Equities
North AmericaEuropeAsiaOceaniaMiddle East� More Equities

Indexes
DOW JONESS&P 500NASDAQ 100TSX COMPFTSE 100� More Indexes

Currency / Forex
EUR / USDGBP / USDUSD / JPYUSD / CADAUD / USD� More Currencies

Commodities
GOLDCrude Oil (WTI)Crude Oil (BRENT)SILVERPLATINUM� More Commodities


 News
Latest News
CompaniesMarketsEconomyCurrency / ForexCommoditiesInterest RatesBusiness LeadersFinancial calendarEconomic calendar

Listed company
Analyst reco.RumorsIPOsCapital Markets TransactionsNew ContractsProfits warningsAppointmentsPress ReleasesEventsCorporate actions

Sector News
EnergyBasic MaterialsIndustrialsConsumer CyclicalConsumer Non-CyclicalFinancialsHealthcareTechnologyTelecommunications ServicesUtilities


 Analysis
All AnalysisCommentariesIndex AnalysisStock Trading StrategiesCommodity AnalysisForex Analysis

 Stock Picks
All stock picks

 Portfolios
My Portfolio
Virtual portfolios
4-Traders Portfolios
European PortfolioUSA PortfolioAsian Portfolio


 Screeners
Market Screener HomeFundamental Analyse
Top Investor RatingTop Trading RatingTop ConsensusGrowth stocksYield stocksLow valuations

Technical Analysis
Oversold stocksOverbought stocksClose to resistancesClose to supportsAccumulation phaseMost volatile stocks


 Watchlists
My Watchlists
Watchlists
Top Lists
Yield stocksGrowth stocksUndervalued Stocks


 Top / Flop
Top News
Most Read NewsHot News

Top Fundamentals
Top CapitalizationTop YieldTop PERTop ConsensusTop Fundamentals

Top Technicals
Top RSIUnusual volumesTop GapsTop STIM

Top Movers
Top USATop CanadaTop U.K.Top GermanyTop EuropeTop Asia


 Tools
Market ScreenerDynamic chartFinancial calendarEconomic calendarSector researchCurrency converter

 Our Services
Premium AccessDiscover our Services

 



















 






4-Traders Homepage  >  News  >  Business Leaders  >  Business Leaders Biography


Business Leaders




Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors HomeAll newsMost read newsBusiness Leaders Biography


 
















Robert Alexander Ingram

Age : 74Public asset : 3,392,169 USDLinked companies :  Valeant Pharmaceuticals Intl Inc -  Cree, Inc. -  BioCryst Pharmaceuticals, Inc. -  HBM Healthcare Investments AG -  Malin Corporation plc -  Novan Inc 





Summary 



Mr. Robert A. Ingram is Chairman at Viamet Pharmaceuticals Corp., Chairman at Novan, Inc., Chairman at Elan Pharmaceuticals, Inc., Chairman at GlaxoSmithKline Foundation, Chairman at North Carolina Glaxosmithkline Foundation, Chairman at Research Triangle Foundation, Chairman at Viamet Pharmaceuticals, Inc., General Partner at Hatteras Venture Partners and a Member at Business-Higher Education Forum.He is on the Board of Directors at BioCryst Pharmaceuticals, Inc., Malin Corp. Plc, Cree, Inc., HBM Healthcare Investments AG, Valeant Pharmaceuticals International, Inc., James B. Hunt Jr. Institute for Educational Leadership & Poli, PhaseBio Pharmaceuticals, Inc., Project HOPE-The-People-To-People HealthFoundation, Inc., Research Triangle Institute, American Cancer Society Foundation and CEO Roundtable on Cancer, Inc. Mr. Ingram was previously employed as an Independent Director by Regeneron Pharmaceuticals, Inc., Non-Executive Chairman by Elan Corp. Plc, an Independent Director by Allergan, Inc., an Independent Director by Edwards Lifesciences Corp., Chairman by OSI Pharmaceuticals, Inc., Non-Executive Director by Misys Plc, Vice Chairman-Pharmaceuticals by Smithkline Beecham Corp., Chief Executive Officer by Glaxo Wellcome Plc, Chairman by Glaxo, Inc., President by Merck Frosst Canada Ltd., Chairman by American Foundation for Pharmaceutical Education, Chairman, President & Chief Executive Officer by Glaxo Wellcome, Inc., Vice President-Public Affairs by Merrell Dow Pharmaceuticals, Inc., a Principal by National Institutes of Health, and Chairman by Novan, Inc.He also served on the board at Lowe's Cos., Inc., Wachovia Corp., H. Lee Moffitt Cancer Center & Research Institute, Inc., ICN Pharmaceuticals, Inc. /Old/, Nortel Networks Corp., Pharmaceutical Product Development LLC and Quintiles Transnational Corp. Mr. Ingram received his BS degree in Business Administration from Eastern Illinois University.



Current positions of Robert Alexander Ingram 









 NameTitle
Since
 Valeant Pharmaceuticals Intl Inc(Pharmaceuticals)
Director
2003 Cree, Inc.(Semiconductors)
Lead Independent Director
2008 BioCryst Pharmaceuticals, Inc.(Biotechnology & Medical Research)
Chairman
2015 HBM Healthcare Investments AG(Investment Management & Fund Operators)
Director
2006 Malin Corporation plc(Pharmaceuticals)
Independent Non-Executive Director
2015 Novan Inc(Pharmaceuticals)
Executive Chairman
2011Viamet Pharmaceuticals, Inc.
Chairman
-Elan Pharmaceuticals, Inc.
Chairman
-Viamet Pharmaceuticals Corp.
Chairman
2014Research Triangle Foundation
Chairman
-GlaxoSmithKline Foundation
Chairman
-North Carolina Glaxosmithkline Foundation
Chairman
-PhaseBio Pharmaceuticals, Inc.
Director
-Research Triangle Institute
Member-Governors Board
-H. Lee Moffitt Cancer Center & Research Institute, Inc.
Director
-American Cancer Society Foundation
Vice Chairman
-CEO Roundtable on Cancer, Inc.
Vice Chairman
-James B. Hunt Jr. Institute for Educational Leadership & Poli
Director
-Hatteras Venture Partners
General Partner
-Business-Higher Education Forum
Member
-



Holdings of Robert Alexander Ingram 










 NameEquities%Valuation

 Valeant Pharmaceuticals Intl Inc (VRX)92,0460.026%1,592,396 USD
 Cree, Inc. (CREE) Semiconductors 61,8160.064%1,523,764 USD
 Novan Inc (NOVN) Pharmaceuticals 57,7770.36%232,841 USD
 BioCryst Pharmaceuticals, Inc. (BCRX) Biotechnology & Medical Research 7,7640.0097%43,168 USD



Robert Alexander Ingram: Personal Network 







 NameLinked companies

G. Kelly Martin Malin Corporation plcNovan IncViamet Pharmaceuticals Corp.Viamet Pharmaceuticals, Inc.Elan Pharmaceuticals, Inc. 

Adrian G. Howd Malin Corporation plcViamet Pharmaceuticals Corp.Viamet Pharmaceuticals, Inc. 

Jeffrey L. Edwards Viamet Pharmaceuticals Corp.Viamet Pharmaceuticals, Inc. 

Philip R. Tracy Viamet Pharmaceuticals Corp.Viamet Pharmaceuticals, Inc. 

S. Edward Torres Viamet Pharmaceuticals Corp.Viamet Pharmaceuticals, Inc. 

Robert J. Schotzinger Viamet Pharmaceuticals Corp.Viamet Pharmaceuticals, Inc. 

Oren J. Cohen Viamet Pharmaceuticals Corp.Viamet Pharmaceuticals, Inc. 

Andrew C. von Eschenbach Viamet Pharmaceuticals Corp.Viamet Pharmaceuticals, Inc. 

Martin J. Murphy American Cancer Society FoundationCEO Roundtable on Cancer, Inc.H. Lee Moffitt Cancer Center & Research Institute, Inc. 

John W. Palmour Cree, Inc.Novan Inc 




Most Read News 




07/17 CHARLES SCHWAB : Low-fee BlackRock funds reel in cash but earnings disappoint



07/17DJCHARLES SCHARF : Bank of New York Mellon Names Former Visa Executive Scharf CEO and Chairman



07/17 PHILIP GREEN : You're hired - UK 'Apprentice' star Brady to chair Philip Green's company



07/17DJRUPERT MURDOCH : Tesla Names James Murdoch and Linda Johnson Rice to Board -- Update



07/17DJJAMES MURDOCH : Tesla Names James Murdoch and Linda Johnson to Board of Directors



07/18DJMARK LIGHT : Top Company News of the Day



07/18DJNELSON PELTZ : Peltz Goes on Offense In Break From Form -- WSJ



07/17 DAVID HENRY : Didn't pay your Macy's bill? Expect a text from Citigroup



07/17DJMARK LIGHT : Top Company News of the Day



07/15DJWARREN BUFFETT : Sprint Dials Up Buffett, Malone -- WSJ



More news

 


            © 2017 People and Ownership :    









Advertisement








Robert Alexander Ingram : Connections 



 Novan Inc









G. Kelly MartinJohn W. Palmour




 FibroGen Inc









Jeffrey L. Edwards




 Bio-Rad Laboratories, Inc.









Jeffrey L. Edwards




 GlobeImmune Inc









S. Edward Torres




 Malin Corporation plc









G. Kelly MartinAdrian G. Howd




CEO Roundtable on Cancer, Inc.
                                            








Martin J. Murphy





Wren Therapeutics Ltd.
                                            








G. Kelly MartinAdrian G. Howd





Duke University
                                            








Oren J. Cohen





Viamet Pharmaceuticals Corp.
                                            








G. Kelly MartinJeffrey L. EdwardsPhilip R. TracyS. Edward TorresRobert J. SchotzingerOren J. CohenAndrew C. von Eschenbach





Esanex, Inc.
                                            








S. Edward Torres





Brandon Point Industries Ltd.
                                            








G. Kelly MartinAdrian G. Howd





National Comprehensive Cancer Network Foundation
                                            








Andrew C. von Eschenbach





Immunocore Ltd.
                                            








G. Kelly MartinAdrian G. Howd





Serenus Biotherapeutics, Inc.
                                            








G. Kelly Martin





Poseida Therapeutics, Inc.
                                            








G. Kelly MartinAdrian G. Howd





Elan Pharma Ltd.
                                            








G. Kelly Martin





Viamet Pharmaceuticals Holdings LLC
                                            








G. Kelly MartinJeffrey L. Edwards





Elan Pharmaceuticals, Inc.
                                            








G. Kelly Martin





Malin Life Sciences Holdings Ltd.
                                            








G. Kelly Martin





Manhattan Institute For Policy Research, Inc.
                                            








Andrew C. von Eschenbach





 







Popular Business Leaders 


 

Bernard Arnault
Mary Barra
Lloyd Blankfein
Michael Bloomberg
Yannick Bollor�
Warren Buffett
Antony Burgmans
Jean-paul Clozel
Gary Cohn
Jamie Dimon
Ralph Dommermuth
Sebastian Ebel
John Edwards
David Einhorn
Jeff Fettig
Mark Fields
Carlos Ghosn
Terry Gou
David Henry
Carl Icahn
Li Ka-shing
Michel Landel
Daniel Loeb
Jack Ma
Marissa Mayer
Lakshmi Mittal
Oscar Munoz
Rupert Murdoch
Elon Musk
Peter Nicholas
John Paulson
Nelson Peltz
Georges Plassat
Hasso Plattner
Thomas Rabe
Giuseppe Recchi
Wolfgang Reitzle
Urs Rohner
Wilbur Ross
Charles Schwab
Igor Sechin
Pascal Soriot
George Soros
Rupert Stadler
Bernard Tapie
John Williamson
Thomas Wilson
Dieter Zetsche
Mark Zuckerberg



A-Z Business Leaders




 



























4-traders.com :MarketsNewsAnalysisStock PicksPortfoliosScreenersWatchlistsTop / FlopToolsOur ServicesAbout :Surperformance SASContact usAdvertiseLegal informationsAbout usStay Connected :FacebookTwitterPartners :B�rse: Aktien, Kurse und NachrichtenBest tweets 




   Copyright � 2017 Surperformance. All rights reserved.  












 














Slave
















 


      Alexander Robert Ingram - Insider Monkey                          Companies 0 See All     Hedge Funds 0 See All    Insiders 0 See All    Institutional Investors 0 See All   Click here to see all  results for  Sorry, no results has been found matching your query.                   Adblocker Detected    Dear Valued Visitor, We have noticed that you are using an ad blocker software.
    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. To view this article, you can disable your ad blocker and refresh this page or simply login. We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.       Home > Insider Trading > Alexander Robert Ingram
				> Profile    Alexander Robert Ingram    Profile Insider Purchases Insider Sales News      Affiliations  Director at Novan Inc. (NOVN), 2017-06-07 Director at Biocryst Pharmaceuticals Inc (BCRX), 2017-06-02 Large Shareholder at G1 Therapeutics Inc. (GTHX), 2017-05-25 Director at Cree Inc (CREE), 2017-04-27 Director at Valeant Pharmaceuticals International Inc. (VRX), 2017-04-04 Large Shareholder, Other at Clearside Biomedical Inc. (CLSD), 2017-01-20 Director at Regeneron Pharmaceuticals Inc (REGN), 2015-05-27 Director at Edwards Lifesciences Corp (EW), 2015-05-19 Director at Allergan Inc (AGN), 2012-10-31 Director at Pharmaceutical Product Development Inc (PPDI), 2011-12-06 Director at Lowes Companies Inc (LOW), 2011-04-04 Director at Valeant Pharmaceuticals International (VRX), 2010-10-01 Director at Osi Pharmaceuticals Inc (OSIP), 2010-06-09 Director at Wachovia Corp New (WB), 2009-01-02     Insider Trading: Purchases See All      Company Symbol Price Amount Relationship Remaning Holdings Date Form 4    Cree Inc CREE $18.95 1,000 Director 4,750 2009-03-06 Filing     Insider Trading: Sales See All      Company Symbol Price Amount Relationship Remaining Holdings Date Form 4    Cree Inc CREE $27.67 3,750 Director 48,846 2015-12-01 Filing   Regeneron Pharmaceuticals Inc REGN $513.39 1,379 Director 1,500 2015-05-27 Filing   Edwards Lifesciences Corp EW $90.26 12,500 Director 30,541 2014-07-31 Filing   Edwards Lifesciences Corp EW $87.72 15,000 Director 36,856 2012-05-25 Filing   Edwards Lifesciences Corp EW $87.79 10,000 Director 46,302 2011-05-09 Filing                Home Hedge Funds Markets Blog Authors About Us Contact Us Privacy Policy Terms of Use Site Map  All text and design is copyright ©2016 Koala Guide LLC. All rights reserved.             

Robert Ingram, Hatteras Venture Partners: Profile & Biography - Bloomberg


































































  


































Feedback





Robert "Bob" Ingram

General Partner,
Hatteras Venture Partners






Career History




Chairman
Novan Inc, 2/2016-PRESENT


General Partner
Hatteras Venture Partner III LP, 1/2007-PRESENT


General Partner
Hatteras Venture Partners, 1/2007-PRESENT


Strategic Advisor
Glaxosmithkline PLC, 1/2010-12/2012


Chairman
Valeant Pharmaceuticals Intl Inc, 12/2010-3/2011


Chairman
Osi Pharmaceuticals Inc, 1/2003-6/2010


Vice Chairman:Pharmaceuticals
Glaxosmithkline PLC, 1/2003-2009


Chairman
Valeant Pharmaceuticals Intl, 8/2006-2/2008


Pres:Pharmaceutical Ops/COO
Glaxosmithkline PLC, 1/2001-1/2003


Chairman/CEO
Glaxo Wellcome Inc, 1/1999-12/2000


Chief Executive Officer
Glaxo Wellcome PLC, 1/1999-12/2000


Chief Executive Officer
Glaxo Wellcome PLC, 10/1997-1/1999


Executive Director
Glaxo Wellcome PLC, 9/1996-10/1997


President/CEO
Glaxo Wellcome Inc, 5/1995-10/1997


President/CEO
Glaxo Inc, 3/1994-5/1995


President/COO
Glaxo Inc, 6/1993-3/1994


Executive Vice President
Glaxo Inc, 1/1993-6/1993



Glaxo Inc, 1990-1/1993


President
Merck Frosst Canada Inc, 1988-1990


VP:Government Affairs
Merck & Co Inc, 1985-1988


VP:Public Affairs
Merrell Dow Pharmaceuticals, UNKNOWN-1985


Chairman
Glaxo Inc, 1/1999-UNKNOWN


Special Consultant
Glaxosmithkline PLC, FORMER


Sales Representative
Merrell Dow Pharmaceuticals, FORMER


Chairman
Nippon Glaxo, FORMER


Show More









Website:
www.hatterasvp.com






Corporate Information
Address:

280 South Mangum Street
Suite 350
Durham, NC 27701
United States


Phone:
1-919-484-0730


Fax:
1-919-484-0364


Web url:
www.hatterasvp.com











From The Web












Personal Information



Education



Eastern Illinois University
Bachelor's Degree, Business Administration








Memberships



Board Memberships




Hbm Bioventures Switzerland


Board Member, PRESENT




Phasebio Pharmaceuticals Inc


Board Member, PRESENT




Research Triangle Inst


Board Member, PRESENT




Malin Corp PLC


Board Member, PRESENT




Viamet Pharmaceuticals Holdings LLC


Board Member, PRESENT




Hbm Healthcare Investments AG


Board Member, PRESENT




Biocryst Pharmaceuticals Inc


Chairman, 5/2017-PRESENT




Novan Inc


Chairman, 2/2016-PRESENT




Viamet Pharmaceuticals Inc


Chairman, 2015-PRESENT




Cree Inc


Lead Director, 10/2011-PRESENT




Biocryst Pharmaceuticals Inc


Board Member, 8/2015-5/2017




Valeant Pharmaceuticals International Inc


Board Member, 5/2016-5/2017




Valeant Pharmaceuticals International Inc


Chairman, 2/2016-5/2016




Valeant Pharmaceuticals International Inc


Interim Chairman, 1/2016-2/2016




Valeant Pharmaceuticals International Inc


Lead Director, 3/2011-1/2016




Regeneron Pharmaceuticals


Board Member, 4/2014-11/2015




Edwards Lifesciences Corp


Board Member, 2/2003-7/2015




Elan Corp PLC


Chairman, 1/2011-2013




Allergan Inc


Board Member, 1/2005-12/2012




Pharmaceutical Product Development LLC


Board Member, UNKNOWN-2011




Cree Inc


Board Member, 12/2008-10/2011




Lowe's Cos Inc


Board Member, 2001-5/2011




Valeant Pharmaceuticals Intl Inc


Chairman, 12/2010-3/2011




Elan Corp PLC


Board Member, 12/2010-1/2011




Valeant Pharmaceuticals Intl Inc


Lead Director, 9/2010-12/2010




Valeant Pharmaceuticals Intl


Lead Director, 2/2008-12/2010




Biovail Corp


Lead Director, 2003-9/2010




Osi Pharmaceuticals Inc


Chairman, 1/2003-6/2010




Wachovia Corp


Board Member, 2001-12/2008




Valeant Pharmaceuticals Intl


Chairman, 8/2006-2/2008




Valeant Pharmaceuticals Intl


Board Member, 11/2003-8/2006




Nortel Networks Corp


Board Member, 3/2000-5/2006




Misys PLC


Board Member, 1/2002-9/2005




Icn Pharmaceuticals Inc


Board Member, 5/2003-11/2003




Molson Inc


Board Member, 6/2002-7/2002




Glaxo Wellcome Inc


Chairman, 1/1999-12/2000




Glaxo Wellcome PLC


Chairman, 10/1997-12/2000




Glaxo Wellcome PLC


Board Member, 5/1995-10/1997




Nippon Glaxo


Chairman, FORMER




Nortel Networks Ltd


Board Member, FORMER




Novan Inc


Board Member, 2011-UNKNOWN




Quintiles Transnatl Corp


Board Member, 2/2004-UNKNOWN




Glaxo Inc


Chairman, 1/1999-UNKNOWN



Show More





Other Memberships




Ceo Roundtable on Cancer


Board Member




Life Beyond Cancer Fdtn


Board Member




Research Triangle Institute


Member




Glaxo North Carolina Foundation


Chairman




James B. Hunt JR. Institute for Educational Leadership 


Board Member




 H Lee Moffitt Cancer Center


Member



Show More








Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data



































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft













Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          











Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          











Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          


















Amazon.com: Amazon Music Unlimited








































Interesting Finds Updated Daily










Amazon




    Try Prime
  


















Digital Music



All Departments
Alexa Skills
Amazon Devices
Amazon Video
Amazon Warehouse Deals
Appliances
Apps & Games
Arts, Crafts & Sewing
Automotive Parts & Accessories
Baby
Beauty & Personal Care
Books
CDs & Vinyl
Cell Phones & Accessories
Clothing, Shoes & Jewelry
   Women
   Men
   Girls
   Boys
   Baby
Collectibles & Fine Art
Computers
Courses
Credit and Payment Cards
Digital Music
Electronics
Gift Cards
Grocery & Gourmet Food
Handmade
Health, Household & Baby Care
Home & Business Services
Home & Kitchen
Industrial & Scientific
Kindle Store
Luggage & Travel Gear
Luxury Beauty
Magazine Subscriptions
Movies & TV
Musical Instruments
Office Products
Patio, Lawn & Garden
Pet Supplies
Prime Exclusive
Prime Pantry
Software
Sports & Outdoors
Tools & Home Improvement
Toys & Games
Vehicles
Video Games
Wine





Go

















Departments









EN

 
      




Hello. Sign inAccount & ListsSign inAccount & ListsOrdersTry PrimeCart0






Your Amazon.comToday's DealsGift Cards & RegistrySellHelpDisability Customer Support 






 Amazon Music Unlimited Prime Music CDs & Vinyl Download Store         Open Web Player MP3 cart Settings













































































































$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          




$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          




$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          
















Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.




Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.




Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.
















Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).




Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).




Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).
















Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More




Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More




Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More


























Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          




Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          




Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          

















There's a problem loading this menu right now.
Learn more about Amazon Prime.






 Get fast, free shipping with Amazon Prime 
 Prime members enjoy FREE Two-Day Shipping and exclusive access to music, movies, TV shows, original audio series, and Kindle books. 

      >
      Get started

















v























